Mini-monoka punctocanaliculoplasty manages canalicular stenosis

Article

Epiphora secondary to punctal and canalicular stenosis is successfully managed by mini-monoka punctocanaliculoplasty.

Epiphora secondary to punctal and canalicular stenosis is successfully managed by mini-monoka punctocanaliculoplasty, according to a study in the British Journal of Ophthalmology.

Dr R.N. Hussain et al., Department of Ophthalmology, Leicester Royal Infirmary, Infirmary Square, Leicester, UK, performed a retrospective case note analysis on 123 eyes of 77 consecutive patients.

Of the eyes studied, 73% had punctal stenosis, 72% had canalicuar stenosis, 46% had both punctal stenosis and canalicuar stenosis, 20% had some severity of lid laxity and 29% had nasolacrimal duct stenosis.

After treatment, 82% of the eyes demonstrated a significant improvement in symptoms. The success rate was raised to 88% when structural comorbidity patients were excluded from the study.

It was discovered that mini-monoka punctocanaliculoplasty is an effective, safe, simple and fairly non-invasive treatment for epiphora secondary to punctal and/or canalicular stenosis.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.